Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Stock Forecast

Stock Price Forecast

According to 6 professional analysts, the 12-month price target for Karyopharm Therapeutics stock ranges from a low of $10 to a high of $56. The average analyst price target of $22.17 forecasts a 285.57% increase in the stock price over the next year.

Price Target: $22.17 (+285.57%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$10	$22.17	$19	$56
Change	+73.91%	+285.57%	+230.43%	+873.91%

* Price targets were last updated on Nov 4, 2025.

Analyst Ratings

The average analyst rating for Karyopharm Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25
Strong Buy	1	1	1	2	2	2
Buy	5	4	4	5	5	4
Hold	1	1	1	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	6	6	7	7	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $30 → $19	Buy	Maintains	$30 → $19	+230.43%	Nov 4, 2025
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Hold → Strong Buy Upgrades $15	Hold → Strong Buy	Upgrades	$15	+160.87%	Oct 13, 2025
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $15 → $12	Buy	Reiterates	$15 → $12	+108.70%	Oct 9, 2025
Michael Ulz Baird	Baird	Buy Maintains $25 → $21	Buy	Maintains	$25 → $21	+265.22%	Oct 9, 2025
Michael Ulz Baird	Baird	Buy Maintains $42 → $25	Buy	Maintains	$42 → $25	+334.78%	Aug 12, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

150.79M

Increased by 3.82%

from 145.24M

Revenue Next Year

155.59M

Increased by 3.18%

from 150.79M

EPS This Year

-12.40

from -14.00

EPS Next Year

-5.81

from -12.40

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	108.09M	209.82M	157.07M	146.03M	145.24M	150.79M	155.59M
Revenue Growth	164.31%	94.12%	-25.14%	-7.03%	-0.55%	3.82%	3.18%
EPS	-40.87	-24.75	-30.30	-18.79	-14.00	-12.40	-5.81
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	8	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	158.9M	180.6M
Avg	150.8M	155.6M
Low	142.4M	129.6M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	9.4%	19.8%
Avg	3.8%	3.2%
Low	-1.9%	-14.0%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	-11.04	-2.29
Avg	-12.40	-5.81
Low	-13.52	-10.05

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.